Tirzepatide (CAS No.: 2023788-19-2) - Dual GIP/GLP-1 Receptor Agonist for Type 2 Diabetes & Obesity

As a professional supplier of pharmaceutical-grade peptide active pharmaceutical ingredients (APIs), we provide high-purity Tirzepatide that strictly complies with global pharmacopoeia standards (USP, EP, BP). A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, it offers superior glycemic control and weight reduction by targeting two key incretin pathways-making it a breakthrough therapeutic agent for type 2 diabetes mellitus (T2DM) and chronic obesity management.

Product Basic Information

Product Core Functions & Applications

Tirzepatide CAS#2023788-19-2 exerts its pharmacological effects by simultaneously activating GIP and GLP-1 receptors-a unique mechanism that synergistically regulates glucose metabolism and body weight. GIP enhances insulin secretion and reduces food intake, while GLP-1 suppresses glucagon, slows gastric emptying, and further reduces appetite. Its key advantage is a long half-life (~5 days), allowing once-weekly administration with sustained efficacy. It is exclusively used in human pharmaceutical formulations:

1. Type 2 Diabetes Mellitus (T2DM) Treatment

Monotherapy: For patients with T2DM inadequately controlled by lifestyle modifications, it reduces glycated hemoglobin (HbA1c) by 1.5-2.0% and fasting blood glucose by 30-50 mg/dL.

Combination Therapy: Used with metformin, SGLT2 inhibitors, or insulin to achieve superior glycemic control compared to single incretin agonists-with HbA1c reductions up to 2.5% in triple therapy.

Cardiometabolic Benefits: Improves multiple cardiovascular risk factors, including blood pressure, triglycerides, and waist circumference, in addition to glycemic control.

2. Chronic Obesity Management

Indicated for adults with a body mass index (BMI) ≥30 kg/m² (obesity) or BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, T2DM).

Achieves significant weight loss (average 15-20% of baseline weight over 72 weeks)-superior to single GLP-1 agonists-by combining GIP-mediated energy expenditure enhancement with GLP-1-induced appetite suppression.

Dosage Forms

Injectable Formulations: Pre-filled pens (2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL) for subcutaneous injection (abdomen, thigh, upper arm), administered once weekly. Dose escalation (starting from 2.5 mg) minimizes gastrointestinal side effects.

Quality & Safety Assurance

as a novel dual-action peptide API, requires stringent quality control to ensure efficacy, stability, and safety:

Raw Material Sourcing & Production

Precursor Selection: Uses high-purity recombinant GIP/GLP-1 hybrid peptide precursors and synthetic modifications (e.g., lipidation for extended half-life) to optimize receptor binding affinity and minimize immunogenicity.

Manufacturing Process: Produced in GMP-certified cleanrooms via advanced solid-phase peptide synthesis (SPPS) and post-translational lipid conjugation. Strict control over coupling efficiency, purification (multi-step HPLC), and lyophilization ensures batch-to-batch consistency and long-term stability.

Comprehensive Testing Protocols

Each batch undergoes rigorous testing to meet global pharmacopoeia standards:

Purity & Related Substances: HPLC analysis (purity ≥99.0%, single impurity ≤0.5%, total impurities ≤1.0%).

Peptide Identity: Confirmed via mass spectrometry and amino acid sequence verification.

Physical & Chemical Tests: Specific optical rotation (+55° to +65°, in 0.1M acetic acid), moisture content (Karl Fischer method ≤3.0%), and pH (6.5-7.5 for reconstituted solution).

Safety Tests: Heavy metal detection (ICP-MS), microbial limit testing (total aerobic microbial count ≤100 CFU/g), sterility testing (for injectable-grade API), and endotoxin testing (≤0.25 EU/mg).

Safety Reminders

Common Side Effects: Gastrointestinal reactions (nausea, diarrhea, vomiting, constipation)-similar to GLP-1 agonists but generally mild to moderate, improving with dose escalation.

Pancreatitis: Monitor for severe persistent abdominal pain; discontinue if suspected.

Thyroid C-Cell Tumor Risk: Contraindicated in patients with personal/family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Hypoglycemia: Risk increases with concurrent insulin or sulfonylureas-reduce doses of these agents by 20-50% initially.

Renal Events: May cause acute kidney injury in patients with dehydration (due to vomiting/diarrhea); ensure adequate fluid intake.

Contraindications: Hypersensitivity to Tirzepatide or any excipients; MTC history/family history; MEN 2.

Cooperation & Contact

We supply pharmaceutical-grade Tirzepatide CAS#2023788-19-2 API for manufacturers of once-weekly injectable formulations, with flexible production capacities (from gram-level R&D samples to kilogram-level bulk orders). If you are a pharmaceutical enterprise, R&D institution, or formulator in need of this product, please contact us for:

Detailed pharmacopoeia compliance documents (USP/EP monograph confirmation, certificate of analysis).

Pricing quotes, bulk order discounts, and free R&D sample requests.

Technical support (e.g., formulation compatibility, reconstitution guidelines, peptide stability protocols).

Contact Information:

Email: sales@huarongpharma.com

Phone/WhatsApp: +86 13751168070

We adhere to the principles of "quality first, compliance-oriented" and look forward to establishing long-term, mutually beneficial cooperative relationships with global partners!

Frequently Asked Questions (FAQs)

1. What are the common side effects of Tirzepatide?

The most common side effects are gastrointestinal reactions, including nausea (35-50% of patients), diarrhea (25-40%), vomiting (15-25%), constipation (10-20%), and decreased appetite (30-45%). These are typically dose-dependent, occur within the first 4-6 weeks, and often improve with continued use or slower dose escalation. Less common side effects include headache, fatigue, and mild injection site reactions (redness, itching).

2. How does Tirzepatide work in the body?

works through a dual mechanism by activating both GIP and GLP-1 receptors:

GIP Receptor Activation: Enhances insulin secretion (glucose-dependent), reduces glucagon release, and may increase energy expenditure-contributing to weight loss.

GLP-1 Receptor Activation: Stimulates insulin secretion, suppresses glucagon, slows gastric emptying (reducing postprandial glucose spikes), and acts on the brain to suppress appetite.

Synergistic Effect: The combination of GIP and GLP-1 actions results in superior glycemic control and greater weight loss compared to single incretin agonists.

Long Half-Life: A lipid chain attached to the peptide binds to albumin, slowing clearance and enabling once-weekly administration.

3. Are there any drug interactions with Tirzepatide?

Yes,is ability to slow gastric emptying may affect absorption of other oral medications. Key interactions include:

Oral Hypoglycemics: Combined use with insulin or sulfonylureas increases hypoglycemia risk-reduce doses of these agents by 20-50% initially.

Oral Contraceptives: May delay absorption (peak concentration reduced by ~25%); administer at least 30 minutes before Tirzepatide injection.

Antibiotics/Antifungals: Drugs requiring rapid absorption (e.g., amoxicillin) should be taken 1 hour before or 2 hours after it.

Beta-Blockers: May mask hypoglycemia symptoms (e.g., tachycardia); monitor blood glucose closely.

Glucocorticoids: May reduce glucose-lowering effect; increase monitoring and adjust doses if needed.